Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Quest Pharmatech Inc V.QPT

Alternate Symbol(s):  QPTFF

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest... see more

TSXV:QPT - Post Discussion

Quest Pharmatech Inc > Interesting
View:
Post by ARIMA11 on Feb 18, 2022 10:34am

Interesting

https://oqp.co.kr/ir/notice/  Of course, QPT.V has not bothered to issue a release on anything. :)

Perhaps they are waiting to see if OQP will meet its deadline. As a result, seems like OQP is gunning for a merger to occur before Feb 24, 2022 to not pay a penality to QPT.V..

Because of the delay QPT.V got OQP to aggree to this: February 24, 2022
; the deadline for the 1% interest-bearing unsecured OQP corporate bond ($1.7M) 

Based on the info below OQP is on track: The effect of the merger occurs after registration.(Article 234 of the Commercial Code) The date of application for the merger is 2022. 02. 21.

 
(1) https://oqp.co.kr/ir/notice/?uid=67&mod=document&pageid=1
MATTERS CONCERNING THE MERGER PROCESS 5-EFFECTIVE SECURITIES REPORT
 
Dear shareholders of Doolites and Doolites Holdings, Hello? I am Lee Kook, who is the representative of Dool-san, and Han-ik, and I, Chang-hyun, the representative of Dool-san
 
The securities statement (merger) submitted to the Financial Supervisory Service is 2022. 02. 10. It has become effective.
 
Currently 2022. 02. 18. As of the merger date, we will protected as scheduled for the merger process to complete it without any difference.
 
In the meantime, thanks to the shareholders who waited.
 
2022. 02. 10
Doolsan and Han Hae
Doolsan Holdings Director Lee Chang-hyun Lee
 
 
(2) https://oqp.co.kr/ir/notice/?uid=68&mod=document&pageid=1
SHAREHOLDER Q&A SESSION OPERATIONS (MERGER RELATED)

Hello shareholders.
 
The securities statement regarding our merger is 2022. 02. 10. It take effect. This securities statement can be be be be be verified through the electronic discovery system DART.
 
We are concerned with the merger regarding the merger, the day before the merger date (2022. 02. 17. We will run a shareholder Q&A session by Thursday).
 
Please email us the question and answer regarding the merger below (to be posted on the homepage).
 
Email address: IPR@oqp.co.kr [Related representative mail of the merger]
 
We hope that we will not be able to answer any questions that are independent of the merger or that we cannot answer. 2022. 02. 18. Q&A sessions are not in operation since the merger date, 2022. 02. 18. Subsequent mail may be be be be be returned. Please refer to it.
 
I will be Canary Bio (formerly Dools), a stock company that always thinks from the shareholders' point of view.
 
Thank you.
 
Canary Bio, Ltd. (formerly Doool)
Representative Nahan-ik
 

(3) https://oqp.co.kr/ir/notice/?uid=69&mod=document&pageid=1
[ONLINE BRIEFING SESSION] CANARYBIO (FORMERLY DOOLS) (2/16 NUMBER, 18:00-19:00, YOUTUBE LIVE)
Hello shareholders.
 
Thank you for showing your interest in running the merger-related shareholder Q&A session.
The question and answer you sent will be be be be be collected and posted to our homepage to share with shareholders.
 
We also want to hold YouTube online briefing sessions by collecting shareholders' inquiries and more.
 
[Guide to the Canary Bio (formerly Doolsan) briefing session]
 
One. Hour: 2022. 02. 16. (Wed) 18:00 to 19:00 (1 hour)
2. YouTube URL: https://youtu.be/g3SZtLFPuLc
*Search window:'Canary Bio'
 
Many participation please.
Thank you.

 
(4) https://oqp.co.kr/ir/notice/?uid=71&mod=document&pageid=1
ANSWERS TO SHAREHOLDER Q&A SESSIONS

Hello shareholders.
 
We will respect to the shareholders' Q&A session by organizing the questions bellow. Additional questions will be be be answered further through the Youtube meeting.
- -
 
Q1: If the two-ollic acid (KOTC) and the two-olated holdings merge, will the two-olated holdings change to the two-olite acid??
 
A: When the merger is complete, the two-all-acid Holdings corporation is absorbed by the two-ollic acid, leaving the two-ollic acid as a persistent corporation. Dools Holdings shareholders hold Dools stock at a rate of 1:1 (one share of Dools per week of Dools Holdings stock). The two-all-duty Holdings stock that you had is extinguished.
 
Q2: How many days is the allocation of two-all-products stock?? Is it possible to trade stocks immediately after assignment? Where is the transaction after the merger??
 
A: The effect of the merger occurs after registration.(Article 234 of the Commercial Code) The date of application for the merger is 2022. 02. 21. This will allow the distribution process to proven through the relative authority when the registration is completed at the registry. We ask for your understanding that the date of stock allocation (initiation) will change according to the schedule of the registry and the relevant authorities, and it is difficult to guide you accurately in this regard. Once the share price is set, we will guide you through the announcement.
Stocks are placed in the securities accounts of shareholders, and can be traded in the K-OTC market in the examing way through security companies, etc.
 
Q3: If the two-all-products holdings merged with the two-all-products to make the transaction possible, how is the stock held?? Will it be the flat of the day the mools are traded??
 
A: Yes, it seats to be wearing at the closing price the day before being born. And the day-to-day deal is the name as being a deal now. Since it is not a new week, there is no formation of Sicho.
 
Q4: There is a possibility of stock drop at the time the actual K-OTC stock price is dividends, do you have any plans for this??
 
A: The “shortcovered” issue of short selling and fewer distributors tend to have soared stock prices in recent years. In this situation, the stock being worn this time may be likely to drop. As the number of distributors increases, I think you will find a reasonable price. The company aim to promote the excellence of oregobab and to receive a reasonable evolution by informing future growth.
 
Q5: At KOTC, the trading volume at the time of the transaction was too low to effect the stock price, but there is a way to respect?
 
A: It is shown that the current number of distributors is small, whatch effects the fluctuations in the stock price. I think volatility will decrease as the distribution stock increases this time. In response, the company plans to actively IR and PR, and will continue to work to innovation the company's stability and growth.
 
Thank you.
 
Canary Bio, Ltd. (formerly Doool)
Representative Nahan-ik

 
Comment by G1945V on Feb 21, 2022 9:53am
ARIMA11, can you make heads and tails of all of this. ??? How did you come about this information??? G1945V
Comment by ARIMA11 on Feb 22, 2022 4:47pm
The source are the OQP & OQP Bio site and it is google translated from Korean to English. As you know, OQP trading was suspended due to an audit issue. As a remedy OQP created a spin off; OQP Bio. OQP Bio is an algamation of multiple units including OncoQuest. Until the merger takes place and OQP and/or OQP Bio trades.. QPT.V is not likely to see any money. Source: https://oqpbio ...more  
Comment by G1945V on Feb 23, 2022 12:28pm
The Immunotherapy Asset Transfer between OncoQuest Inc. ("OncoQuest") and OncoQuest Pharmaceuticals, Inc. ("OQP") will net OncoQuest Inc., approx 80-90 million shares once a public listing for OQP BIO is secured. OQP BIO in total will have approx 165 Million shares.    I guess at some point OncoQuest Inc., will sell "OQP BIO" shares from time to time and ...more  
Comment by ARIMA11 on Feb 24, 2022 1:42pm
The possibility for"no money" is there but QPT.V should have a legal option IF it comes to that! The likelihood is relatively low, in the last release South Korea is a location of one studies. Also the South Korean government is also involved in funding (K-Master Program).   https://questpharmatech.com/wp-content/uploads/2021/09/NR010921.pdf https://k-master.org/intro_3_e ...more